Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection
Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir (GS-5885) Fixed-dose Combination in NS3/4A Protease Inhibitor-experienced Subjects With HCV Genotype 1 Infection and HIV Co-infection
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Rennes, Francia
- Centre de Méthodologie et de Gestion de Rennes
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Confirmed HIV infection
- Infection with HCV genotype 1 only, confirmed at screen visit, with a HCV-RNA ≥ 1000 InternationalUnit(IU)/mL at screen visit
- Treatment-experienced subjects with:
- previous virological failure to tritherapy with Peginterferon/Ribavirin and protease inhibitor,
- or premature discontinuation of previous tritherapy with Peginterferon/Ribavirin and protease inhibitor due to intolerance to Peginterferon or protease inhibitor
- Anti-HCV treatment stopped for at least the last 3 months
- Patients on a stable (for more than 1 month) antiretroviral treatment consisting of an emtricitabine/tenofovir or lamivudine/tenofovir standard of care backbone plus efavirenz or raltegravir or rilpivirine or enfuvirtide. Alternative combinations of the above listed medications may be allowed.
- Dendritic cells 4 > 100/mm3 and > 15% at screen visit
- HIV-RNA < 50cp/ml for more than 3 months at screen visit
- Any liver fibrosis grade, with the assessment of the presence or not of cirrhosis at screening, cirrhosis being defined as a METAVIR score of F4 on the liver puncture biopsy and/or with hepatic impulse elastometry ≥ 14,5 kilopascal (kPa):
Previous liver biopsy exhibiting cirrhosis lesions (METAVIR F4),
- and/or significant liver biopsy (cumulative length ≥ 15mm or ≥ 5 portal spaces), within the past 18 months
- and/or significant and reliable liver stiffness assessment (Fibroscan®) within the past 6 months (at least 10 measures with IQR less than 30% of the median value and a success rate of at least 70%).
- Female patients with child-bearing potential, and their heterosexual partners must use adequate contraception from the date of screening until 90 days after administration of the last dose of study drug. Male participants must agree to consistently and correctly use a condom, while their female partner must use adequate contraception from the date of screening until 90 days after administration of the last dose of study drug
- Body weight ≥40 kg and ≤125 kg
- Informed and signed consent for the main study and the Pharmacokinetic (PK ) sub-study (for the participating patients)
- Patients with Health insurance
Non inclusion Criteria:
- Child-Pugh B or C cirrhosis or history of decompensated cirrhosis.
- Co-infection with Hepatitis B virus (HBV) (AgHBs +) with HBV DNA > 1000 UI/ml
- Pregnant or breast-feeding women
- Transplant recipients
- Opportunistic infections (stage C), active or occurred within 6 months prior to baseline
- Evolutive malignancy, including hepatocarcinoma which should be controlled prior to baseline
- Alcohol or drug consumption which may affect the study participation according to the investigator. Patients included in a programme of substitution with methadone or buprenorphine could be enrolled. The opinion of a consultant in addictology is recommended for patients presenting with current drug use or drug use during the previous year.
- Patients with a history of non-adherence, who will be at risk of being unable to respect the study follow-up timetable
- Patients participating in another clinical trial within 30 days prior to inclusion
- Hb < 10 g/dL (female) or < 11g/dL (male)
- Platelets < 50 000/mm3
- Neutrophil count < 750/mm3
- Renal failure defined as creatinin clearance (MDRD) < 60ml/min
- Other antiretroviral drugs than those allowed in the study
- Contra-indications to Sofosbuvir, Ledipasvir
- Contra-indicated treatment likely to interfere with the study drugs as listed in the protocol
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Sofosbuvir/Ledipasvir
Non-cirrhotic patients will receive SOF/LDV Fixed Dose Combination (FDC) for 12 weeks. Cirrhotic patients will receive SOF/LDV Fixed Dose Combination (FDC) for 24 weeks. |
SOF 400 mg/LDV 90 mg FDC tablet administered orally once daily
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Sustained virologic response 12 weeks after discontinuation of therapy (SVR12), i.e. at week 36.
Periodo de tiempo: 12 weeks post-treatment
|
12 weeks post-treatment
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Adverse clinical and biological events that occur during the treatment and up to 24 weeks after the end of the treatment
Periodo de tiempo: up to 24 weeks after the end of the treatment
|
up to 24 weeks after the end of the treatment
|
|
|
Number and causes of poor adherence and treatment interruptions
Periodo de tiempo: at 1,2,3,4,8,12,16, 20, 24 weeks during treatment, 4, 8,14,18,24 weeks after treatment discontinuationeeks after discontinuation of drugs
|
at 1,2,3,4,8,12,16, 20, 24 weeks during treatment, 4, 8,14,18,24 weeks after treatment discontinuationeeks after discontinuation of drugs
|
|
|
SVR rate 24 weeks (i.e. W48) after the end of treatment and according to the HCV sub-type
Periodo de tiempo: Week 48
|
Week 48
|
|
|
Number of patients with HCV resistance mutations to Sofosbuvir and/or Ledipasvir
Periodo de tiempo: from Day(D)0 to Week (W)24
|
from Day(D)0 to Week (W)24
|
|
|
HCV viral load
Periodo de tiempo: at Day 0, Week 1, 2, 4, 8, 12, 16, 20, week 24, and 4, 8, 12, 18 and 24 weeks after the end of the treatment
|
at Day 0, Week 1, 2, 4, 8, 12, 16, 20, week 24, and 4, 8, 12, 18 and 24 weeks after the end of the treatment
|
|
|
Plasma HIV RNA levels
Periodo de tiempo: at Day 0, Week 4, 8, 12, 16, 20, 24, 36 and Week 48
|
at Day 0, Week 4, 8, 12, 16, 20, 24, 36 and Week 48
|
|
|
Assess drug-drug interactions between HCV et HIV drugs
Periodo de tiempo: Day 0 and Week 4
|
Describe pharmacokinetic parameters of HIV drugs at Day 0 and Week 4 Describe pharmacokinetic parameters of Sofosbuvir and Ledipasvir at Week 4
|
Day 0 and Week 4
|
|
Patient's reported outcomes evaluation
Periodo de tiempo: Day 0, Week 12, Week 24 and Week 36
|
Day 0, Week 12, Week 24 and Week 36
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Silla de estudio: Eric BELLISSANT, Centre de Méthodologie et de Gestion, CHU de Rennes
- Investigador principal: Eric Rosenthal, Hôpital de Nice
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades De Transmisión Sexual Virales
- Enfermedades de transmisión sexual
- Infecciones por lentivirus
- Infecciones por retroviridae
- Síndromes de deficiencia inmunológica
- Enfermedades del sistema inmunológico
- Enfermedades del HIGADO
- Infecciones por Flaviviridae
- Hepatitis, Viral, Humana
- Infecciones por enterovirus
- Infecciones por Picornaviridae
- Infecciones por VIH
- Hepatitis
- Hepatitis A
- Hepatitis C
- Coinfección
- Agentes antiinfecciosos
- Agentes Antivirales
- Sofosbuvir
- Ledipasvir
Otros números de identificación del estudio
Otros números de identificación del estudio
- ANRS HC31 SOFTRIH
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .